TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3595574

Group type: EXPERIMENTAL
Intervention: Pancuronium (single-dose method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium (cumulative-dose method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tubocurarine (single-dose method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tubocurarine (cumulative-dose method)
Number of subjects: 0
Study: 29656977

Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plain Bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Historical Controls
Number of subjects: 80
Study: 29122108

Group type: EXPERIMENTAL
Intervention: Stepping Up intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Non-insulin-treated T2DM
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Both groups (insulin initiators and non-initiators)
Number of subjects: 266
Study: 26222057

Group type: EXPERIMENTAL
Intervention: CAPOX-B plus cetuximab
Number of subjects: 755

Group type: COMPARATOR
Intervention: CAPOX-B
Number of subjects: 755
Study: 23122211

Group type: COMPARATOR
Intervention: Peanut Butter (PB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Whole Peanuts (WP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no peanuts)
Number of subjects: 15
Study: 20371683

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab-CHOP)
Number of subjects: 197

Group type: COMPARATOR
Intervention: CHOP (conventional chemotherapy)
Number of subjects: 197
Study: 18332300

Group type: COMPARATOR
Intervention: Single-dose e-SBI group
Number of subjects: 576

Group type: COMPARATOR
Intervention: Multidose e-SBI group
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Control group (information pamphlet)
Number of subjects: 576
Study: 16983932

Group type: EXPERIMENTAL
Intervention: Azelnidipine (8-16 mg daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 9
Study: 12657407

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) injection of propofol 2 mg/kg followed by inhalation of sevoflurane 3% (Group P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vital capacity inhalation induction with sevoflurane 8% (Group S)
Number of subjects: 40
Study: 10735794

Group type: COMPARATOR
Intervention: Epidural morphine 0 mg (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine 1.25 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine 2.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3.75 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg
Number of subjects: 60
Study: 8959468

Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8232485

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (250 mg every six hours for 3 days followed by oral prednisone (1 mg per kilogram of body weight) for 11 days)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg per kilogram for 14 days)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone compared to placebo
Number of subjects: 389

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone compared to oral prednisone
Number of subjects: 389

Group type: COMPARATOR
Intervention: MRI signal abnormalities (3 or more lesions)
Number of subjects: 389
Study: 2951795

Group type: EXPERIMENTAL
Intervention: Duovent (200 micrograms fenoterol + 80 micrograms ipratropium bromide)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29730666

Group type: EXPERIMENTAL
Intervention: Arginine-containing fluoridated dentifrice (AFD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular fluoridated dentifrice (FD)
Number of subjects: 12
Study: 26886163

Group type: EXPERIMENTAL
Intervention: Automated Bolus Advisor (ABA) meter (Accu‐Chek Aviva Expert)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control phase using a traditional blood glucose meter (Accu‐Chek(®) Aviva Nano)
Number of subjects: 36
Study: 24160304

Group type: EXPERIMENTAL
Intervention: Slow speech rate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Normal speech rate
Number of subjects: 102

Group type: COMPARATOR
Intervention: Fast speech rate
Number of subjects: 102
Study: 23151421

Group type: EXPERIMENTAL
Intervention: TEA (ropivacaine 0.2%+sufentanil)
Number of subjects: 84

Group type: COMPARATOR
Intervention: PVB (ropivacaine 0.5%)+ITO (sufentanil+morphine)
Number of subjects: 84
Study: 20693499

Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17OHPC)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study: 18788652

Group type: EXPERIMENTAL
Intervention: Nonpharmacological sleep therapy for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wait list period
Number of subjects: 21
Study: 16038599

Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluoxetine combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11977509

Group type: EXPERIMENTAL
Intervention: Shu Feng Huo Luo Pian, 2 pills, p.o., bid, supplemented with calcium Caltrate D 0.6 g, p.o., qd for 2 courses (2 weeks each)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sulindac 0.2 g, p.o., bid, supplemented with calcium Caltrate D 0.6 g, p.o., qd for 2 courses (2 weeks each)
Number of subjects: 50
Study: 10067800

Group type: EXPERIMENTAL
Intervention: Telmisartan (20 to 40-80 mg once a day)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Enalapril (5 to 10-20 mg once a day)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 278

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 278
Study: 7669484

Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (50 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (100 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (150 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Digoxin alone (0.375 mg daily)
Number of subjects: 42
Study: 2149048

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 312486

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kanamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study: 30689549

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham-RIC (Control)
Number of subjects: 58
Study: 28965718

Group type: EXPERIMENTAL
Intervention: Vi-TT
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Vi-PS
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (Meningococcal vaccine)
Number of subjects: 112
Study: 26503021

Group type: EXPERIMENTAL
Intervention: Early AED withdrawal starting 4 months after surgery, with intended complete cessation of drugs after 12 months.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Late AED withdrawal starting 12 months after surgery, with intended complete cessation of drugs after 20 months.
Number of subjects: 180
Study: 23504186

Group type: EXPERIMENTAL
Intervention: Alg1 (AV and VV optimization)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard commercial procedures (control)
Number of subjects: 80
Study: 21039927

Group type: EXPERIMENTAL
Intervention: Zilpaterol-HCl (60 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no zilpaterol)
Number of subjects: 12
Study: 19657121

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (sham procedure)
Number of subjects: 78
Study: 17545078

Group type: EXPERIMENTAL
Intervention: Intravenous hemocoagulase acutus at 1 U
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous hemocoagulase acutus at 2 U
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study: 11061989

Group type: EXPERIMENTAL
Intervention: 260 mg/d ascorbate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 260 mg/d ascorbate plus 14 mg/d iron
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8825843

Group type: EXPERIMENTAL
Intervention: Parental presence during lumbar puncture (LP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (parents remaining outside during LP)
Number of subjects: 57
Study: 1449564

Group type: EXPERIMENTAL
Intervention: Ethanol, 1 g/kg within 1 hr
Number of subjects: 0

Group type: COMPARATOR
Intervention: Juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study: 2578421

Group type: EXPERIMENTAL
Intervention: 28-day cycle of adenine arabinoside 5' monophosphate (ARA-AMP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Two 28-day cycles of ARA-AMP separated by a 4-wk rest interval
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 8 weeks of prednisone therapy followed by 28 days of ARA-AMP therapy
Number of subjects: 38
Study: 30915660

Group type: EXPERIMENTAL
Intervention: Tildrakizumab (100 mg dose)
Number of subjects: 2098

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 2098

Group type: EXPERIMENTAL
Intervention: Subjects with increased body weight
Number of subjects: 2098
Study: 30580268

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme (supervised exercise, psychological coaching, nutritional support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme
Number of subjects: 0
Study: 27103030

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 86

Group type: COMPARATOR
Intervention: GlideScope®
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Airtraq®
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: King Vision™
Number of subjects: 86
Study: 24114551

Group type: EXPERIMENTAL
Intervention: Personalized text messaging intervention (4-6 messages daily for 4 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Personalized text messaging intervention
Number of subjects: 18
Study: 21923756

Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 98
Study: 19962118

Group type: EXPERIMENTAL
Intervention: 6-week online intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: 6-week weight and caloric feedback only (via email)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 6-week combined feedback and online intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 170
Study: 18550345

Group type: EXPERIMENTAL
Intervention: Olanzapine full dose (OFD)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Olanzapine reduction dose (ORD)
Number of subjects: 97
Study: 15758738

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 12819915

Group type: EXPERIMENTAL
Intervention: Digital chest radiography combined with dual‐energy chest radiography
Number of subjects: 20

Group type: COMPARATOR
Intervention: Digital chest radiography alone
Number of subjects: 20
Study: 10355212

Group type: EXPERIMENTAL
Intervention: Pain treatment
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Strong opioids
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Analgesics 'as needed'
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Patients' pain knowledge
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Written pain information
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: District nurses informed about patients' pain
Number of subjects: 313
Study: 8594426

Group type: EXPERIMENTAL
Intervention: Intravenous standard heparin
Number of subjects: 400

Group type: COMPARATOR
Intervention: Subcutaneous low-molecular-weight heparin
Number of subjects: 400
Study: 2022110

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1168
Study: 31732102

Group type: EXPERIMENTAL
Intervention: RCTs published in JCP
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: RCTs published in JOP
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: RCTs published in JPR
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Overall RCTs in all journals
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Methodology section adherence
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Results section adherence
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Discussion section adherence
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Highest modified CONSORT score
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Lowest modified CONSORT score
Number of subjects: 369
Study: 29157121

Group type: EXPERIMENTAL
Intervention: Signed family physician reminder letter and standard reminder postcard
Number of subjects: 5638

Group type: COMPARATOR
Intervention: Standard reminder postcard alone
Number of subjects: 5638
Study: 27456835

Group type: EXPERIMENTAL
Intervention: Microvascular disease (history of macroalbuminuria)
Number of subjects: 10624

Group type: EXPERIMENTAL
Intervention: Microvascular disease (retinal photocoagulation therapy)
Number of subjects: 10624

Group type: EXPERIMENTAL
Intervention: Microvascular disease
Number of subjects: 10624

Group type: EXPERIMENTAL
Intervention: Macrovascular disease
Number of subjects: 10624

Group type: EXPERIMENTAL
Intervention: Major PAD (composite outcome)
Number of subjects: 10624
Study: 25303507

Group type: EXPERIMENTAL
Intervention: Isolite system (IS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rubber dam (RD)
Number of subjects: 42
Study: 22707262

Group type: EXPERIMENTAL
Intervention: 20 g of canola oil, soybean oil, or butter
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid rich canola oil
Number of subjects: 29
Study: 20701667

Group type: EXPERIMENTAL
Intervention: capsaicin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: alpha‐lipoic acid
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: lysozyme‐lactoperoxidase
Number of subjects: 56

Group type: COMPARATOR
Intervention: boric acid
Number of subjects: 56
Study: 18559163

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 298
Study: 15722322

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12824969

Group type: EXPERIMENTAL
Intervention: HPV testing at 12 months
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Repeat semiannual cytology with referral to colposcopy at an ASCUS threshold
Number of subjects: 1539

Group type: EXPERIMENTAL
Intervention: Combining cytology and HPV testing
Number of subjects: 1539
Study: 10585165

Group type: EXPERIMENTAL
Intervention: Acute creatine loading (25 g per day for 4 days)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Longer-term creatine supplementation (5 g of creatine per day for 2 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (5 g per day for 2 months)
Number of subjects: 22
Study: 8936571

Group type: EXPERIMENTAL
Intervention: PALS Skills Training
Number of subjects: 296

Group type: COMPARATOR
Intervention: No Skills (Control)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: PALS Skills Training + Normative Education
Number of subjects: 296
Study: 2015161

Group type: EXPERIMENTAL
Intervention: Copper sulphate 20 mg daily (n = 13)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matched placebo (n = 8)
Number of subjects: 21
Study: 6285318

Group type: EXPERIMENTAL
Intervention: CCK‐OP 1.5 U/kg/15 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CCK‐OP 3.0 U/kg/15 min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study: 30408191

Group type: EXPERIMENTAL
Intervention: Decision aid prototype (DA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard care procedures
Number of subjects: 99
Study: 28797260

Group type: EXPERIMENTAL
Intervention: Standardised Patients (SP) workshop with and without video feedback
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual teaching comprising peer role play
Number of subjects: 108
Study: 25669611

Group type: EXPERIMENTAL
Intervention: dezocine 0.1 mg/kg
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: fentanyl 1 μg/kg
Number of subjects: 114

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 114
Study: 23302751

Group type: COMPARATOR
Intervention: Control (4 minutes of passive rest)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maximum voluntary isometric knee extension (3 repetitions of 3‐second isometric knee extension)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maximum voluntary isometric back squat (3 repetitions of 3‐second isometric squat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynamic back squat (3 repetitions of back squats at 90% 1 repetition maximum)
Number of subjects: 12
Study: 21500889

Group type: EXPERIMENTAL
Intervention: Alcohol with distraction
Number of subjects: 159

Group type: COMPARATOR
Intervention: Alcohol without distraction
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: No-alcohol control with distraction
Number of subjects: 159

Group type: COMPARATOR
Intervention: No-alcohol control without distraction
Number of subjects: 159
Study: 19283309

Group type: EXPERIMENTAL
Intervention: Self-adjusting design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permuted-block randomization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimization method
Number of subjects: 0
Study: 17709293

Group type: EXPERIMENTAL
Intervention: 20 mg of diazepam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Visual analogue scale for sedative effects
Number of subjects: 10
Study: 16332662

Group type: EXPERIMENTAL
Intervention: High-glucosinolate broccoli (super broccoli)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard broccoli
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study: 12417875

Group type: EXPERIMENTAL
Intervention: Prednisone (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-resolution computed tomography of the chest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IgE serum isotypic antibodies to A fumigatus
Number of subjects: 0
Study: 9665601

Group type: EXPERIMENTAL
Intervention: Different levels of attention in an auditory experiment
Number of subjects: 0
Study: 7808274

Group type: EXPERIMENTAL
Intervention: Passive exposure to a novel mobile 1, 2, or 3 days later
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive exposure to a novel mobile after the longest exposure delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Original mobile exposure after the longest delay
Number of subjects: 0
Study: 2582638

Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 0
Study: 805264

Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride (24 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (800 mg/day)
Number of subjects: 36
Study: 30935619

Group type: EXPERIMENTAL
Intervention: GentleWave
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Side-vented needle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EndoVac
Number of subjects: 30
Study: 29122087

Group type: EXPERIMENTAL
Intervention: 8 mg/mL triamcinolone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 16 mg/mL triamcinolone
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 90
Study: 25827670

Group type: EXPERIMENTAL
Intervention: Vitamin D3 megadose supplementation (200,000 IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23161645

Group type: EXPERIMENTAL
Intervention: 40 mg oral prednisone given daily for 10 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: 50 mg etanercept given subcutaneously at randomisation and 1 week later
Number of subjects: 81
Study: 21810257

Group type: EXPERIMENTAL
Intervention: Fiber (25 g) plus rosuvastatin 40 mg
Number of subjects: 116

Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg alone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sinvastatin 40 mg plus ezetimibe 10 mg plus fiber (25 g)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sinvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 116
Study: 19369367

Group type: EXPERIMENTAL
Intervention: Lysine intake of 5 mg x kg(‐1) x d(‐1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lysine intake of 20 mg x kg(‐1) x d(‐1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lysine intake of 35 mg x kg(‐1) x d(‐1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lysine intake of 70 mg x kg(‐1) x d(‐1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Adaptation periods of 8 h, 3 d, or 7 d
Number of subjects: 5
Study: 16672739

Group type: EXPERIMENTAL
Intervention: Childhood sexual assault
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family factors (including parental conflict resolution)
Number of subjects: 0
Study: 15160250

Group type: EXPERIMENTAL
Intervention: Daytime application of the SIII appliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent forces from the SIII appliance
Number of subjects: 0